FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312702944> ?p ?o ?g. }

• W4312702944 endingPage "37" @default.
• W4312702944 startingPage "32" @default.
• W4312702944 abstract "Introduction. We present the recommendations for treatment of the lower-risk myelodysplastic syndromes on behalf of the Serbian myelodysplastic syndromes group. Material and Methods. A literature review was conducted using the following bibliographic databases: Google Scholar, MEDLINE and Kobson. The recommendations for treatment of lower-risk myelodysplastic syndromes are based on expert opinion based on review of the literature and contemporary recommendations for treatment of lower risk myelodysplastic syndromes. Recommendations. Anemia is the most relevant cytopenia in terms of frequency and symptoms in lower-risk myelodysplastic syndromes, and may be treated successfully with erythropoietic stimulating agents, with or without granulocyte growth factor, provided a careful selection is performed on the basis of Revised International Prognostic Scoring System, endogenous erythropoietin levels, and transfusion independence. In case a patient fails erythropoietic stimulating agents treatment, the available options may include lenalidomide, hypomethylating agents, and a rather large number of experimental agents. Chelation therapy is recommended in patients who have received or are anticipated to receive > 20 red blood cell transfusions and those with serum ferritin levels > 2500 ng/mL. Specific therapy for thrombocytopenia has been proposed in experimental clinical trials with thrombomimetic agents that have shown good efficacy, but raised some safety concern. Severe neutropenia is targeted symptomatically with growth factor supportive care. The immunosuppressive treatments are indicated mainly for pancytopenia, hypoplastic lowerrisk myelodysplastic syndromes. Finally, hematopoietic stem cell transplantation is the curative option for younger, good performance (fit) lower-risk patient with poor risk features, according to European Blood and Marrow Transplantation/European Leukemia Net International expert panel and myelodysplastic syndrome-RIGHT group. Conclusion. Treatment of myelodysplastic syndromes is mainly based on resolution of symptoms due to particular cytopenia(s)." @default.
• W4312702944 created "2023-01-05" @default.
• W4312702944 creator A5026333385 @default.
• W4312702944 creator A5063294244 @default.
• W4312702944 creator A5068420742 @default.
• W4312702944 date "2022-01-01" @default.
• W4312702944 modified "2023-09-25" @default.
• W4312702944 title "Treatment of lower-risk myelodysplastic syndrome" @default.
• W4312702944 cites W1541533982 @default.
• W4312702944 cites W1602160610 @default.
• W4312702944 cites W1946552810 @default.
• W4312702944 cites W1970566157 @default.
• W4312702944 cites W1974842446 @default.
• W4312702944 cites W1978522934 @default.
• W4312702944 cites W1990355537 @default.
• W4312702944 cites W2004089260 @default.
• W4312702944 cites W2028751390 @default.
• W4312702944 cites W2030094742 @default.
• W4312702944 cites W2034349976 @default.
• W4312702944 cites W2057876801 @default.
• W4312702944 cites W2060095972 @default.
• W4312702944 cites W2078294866 @default.
• W4312702944 cites W2087821794 @default.
• W4312702944 cites W2103603475 @default.
• W4312702944 cites W2113271378 @default.
• W4312702944 cites W2113736257 @default.
• W4312702944 cites W2125438418 @default.
• W4312702944 cites W2134292391 @default.
• W4312702944 cites W2146920419 @default.
• W4312702944 cites W2155962669 @default.
• W4312702944 cites W2158324181 @default.
• W4312702944 cites W2165036959 @default.
• W4312702944 cites W2178319234 @default.
• W4312702944 cites W2233122712 @default.
• W4312702944 cites W2320100523 @default.
• W4312702944 cites W2320702474 @default.
• W4312702944 cites W2326726820 @default.
• W4312702944 cites W2463012969 @default.
• W4312702944 cites W2531364743 @default.
• W4312702944 cites W2559601897 @default.
• W4312702944 cites W2584597412 @default.
• W4312702944 cites W2784405738 @default.
• W4312702944 cites W2980304971 @default.
• W4312702944 cites W3036602249 @default.
• W4312702944 doi "https://doi.org/10.2298/mpns22s1032m" @default.
• W4312702944 hasPublicationYear "2022" @default.
• W4312702944 type Work @default.
• W4312702944 citedByCount "0" @default.
• W4312702944 crossrefType "journal-article" @default.
• W4312702944 hasAuthorship W4312702944A5026333385 @default.
• W4312702944 hasAuthorship W4312702944A5063294244 @default.
• W4312702944 hasAuthorship W4312702944A5068420742 @default.
• W4312702944 hasBestOaLocation W43127029441 @default.
• W4312702944 hasConcept C104317684 @default.
• W4312702944 hasConcept C126322002 @default.
• W4312702944 hasConcept C143998085 @default.
• W4312702944 hasConcept C150194340 @default.
• W4312702944 hasConcept C177713679 @default.
• W4312702944 hasConcept C185592680 @default.
• W4312702944 hasConcept C190727270 @default.
• W4312702944 hasConcept C2776063141 @default.
• W4312702944 hasConcept C2776364478 @default.
• W4312702944 hasConcept C2776694085 @default.
• W4312702944 hasConcept C2777063308 @default.
• W4312702944 hasConcept C2778248108 @default.
• W4312702944 hasConcept C2779382419 @default.
• W4312702944 hasConcept C2780007613 @default.
• W4312702944 hasConcept C2780235182 @default.
• W4312702944 hasConcept C2780240888 @default.
• W4312702944 hasConcept C2780366003 @default.
• W4312702944 hasConcept C2780817109 @default.
• W4312702944 hasConcept C2911091166 @default.
• W4312702944 hasConcept C55493867 @default.
• W4312702944 hasConcept C71924100 @default.
• W4312702944 hasConceptScore W4312702944C104317684 @default.
• W4312702944 hasConceptScore W4312702944C126322002 @default.
• W4312702944 hasConceptScore W4312702944C143998085 @default.
• W4312702944 hasConceptScore W4312702944C150194340 @default.
• W4312702944 hasConceptScore W4312702944C177713679 @default.
• W4312702944 hasConceptScore W4312702944C185592680 @default.
• W4312702944 hasConceptScore W4312702944C190727270 @default.
• W4312702944 hasConceptScore W4312702944C2776063141 @default.
• W4312702944 hasConceptScore W4312702944C2776364478 @default.
• W4312702944 hasConceptScore W4312702944C2776694085 @default.
• W4312702944 hasConceptScore W4312702944C2777063308 @default.
• W4312702944 hasConceptScore W4312702944C2778248108 @default.
• W4312702944 hasConceptScore W4312702944C2779382419 @default.
• W4312702944 hasConceptScore W4312702944C2780007613 @default.
• W4312702944 hasConceptScore W4312702944C2780235182 @default.
• W4312702944 hasConceptScore W4312702944C2780240888 @default.
• W4312702944 hasConceptScore W4312702944C2780366003 @default.
• W4312702944 hasConceptScore W4312702944C2780817109 @default.
• W4312702944 hasConceptScore W4312702944C2911091166 @default.
• W4312702944 hasConceptScore W4312702944C55493867 @default.
• W4312702944 hasConceptScore W4312702944C71924100 @default.
• W4312702944 hasIssue "Suppl. 1" @default.
• W4312702944 hasLocation W43127029441 @default.
• W4312702944 hasOpenAccess W4312702944 @default.

• next